Neoadjuvant Patritumab Deruxtecan ± Letrozole Shows Efficacy in High-Risk HR+/HER2- Breast Cancer.
- Published in:
- OncologyLive, 2025, v. 26, n. 2, p. 68
- By:
- Publication type:
- Article
Works matching IS 23745347 AND DT 2025 AND VI 26 AND IP 2
Results: 14
1
2
Imlunestrant With or Without Abemaciclib Boosts PFS in ESR1+, ER+/HER2- Advanced Breast Cancer.
- Published in:
- OncologyLive, 2025, v. 26, n. 2, p. 64
- By:
- Publication type:
- Article
3
Taletrectinib Displays Efficacy, Tolerability in ROS1+ NSCLC in Multiple Clinical Trials.
- Published in:
- OncologyLive, 2025, v. 26, n. 2, p. 60
- By:
- Publication type:
- Article
4
What Clinicians and Patients Think About Sharing Social Determinants of Health Data.
- Published in:
- OncologyLive, 2025, v. 26, n. 2, p. 58
- By:
- Publication type:
- Article
5
Novel Index Identifies Social Vulnerability Barriers to Cancer Clinical Trial Enrollment.
- Published in:
- OncologyLive, 2025, v. 26, n. 2, p. 57
- By:
- Publication type:
- Article
6
TARGETING MENIN: A New Frontier in Treating Refractory Leukemias.
- Published in:
- OncologyLive, 2025, v. 26, n. 2, p. 52
- By:
- Publication type:
- Article
7
Frontline Camrelizumab/Rivoceranib Combination Shows Promise in Unresectable HCC.
- Published in:
- OncologyLive, 2025, v. 26, n. 2, p. 46
- By:
- Publication type:
- Article
8
BTK Degraders May Be a Promising Approach in CLL/SLL for Patients With Disease Progression.
- Published in:
- OncologyLive, 2025, v. 26, n. 2, p. 44
- By:
- Publication type:
- Article
9
Tumor-Agnostic Approvals of T-DXd and Repotrectinib Carry the Field Forward.
- Published in:
- OncologyLive, 2025, v. 26, n. 2, p. 40
- By:
- Publication type:
- Article
10
Combination Regimens Expand CLL Treatment Paradigm.
- Published in:
- OncologyLive, 2025, v. 26, n. 2, p. 36
- By:
- Publication type:
- Article
11
Zanidatamab Proves Efficacious in Pretreated Biliary Tract Cancer With Potential to Move to the Frontline.
- Published in:
- OncologyLive, 2025, v. 26, n. 2, p. 30
- By:
- Publication type:
- Article
12
Perspectives on FDA Oncology Approvals and Withdrawals That Shaped 2024.
- Published in:
- OncologyLive, 2025, v. 26, n. 2, p. 14
- By:
- Publication type:
- Article
13
Prognostic vs Predictive Factors in Oncology Carry Differing Intent but May Have Complementary Clinical Utility.
- Published in:
- OncologyLive, 2025, v. 26, n. 2, p. 12
- By:
- Publication type:
- Article
14
Most Notable FDA Approvals in 2024 Include Biomarker-Based Indications.
- Published in:
- OncologyLive, 2025, v. 26, n. 2, p. 7
- By:
- Publication type:
- Article